Ocrelizumab Slows Disability Progression in Advanced Progressive Multiple Sclerosis
The phase III trial found a 30% lower risk of disability progression and a 52% lower need for a wheelchair in more disabled patients.
5 Articles
5 Articles
A drug already used against multiple sclerosis could radically change the management of the progressive forms of the disease, including the most advanced and disabling ones. It is evident from the results of the International Phase III Study Oratory-Hand, coordinated by Queen Mary University in London and published in the scientific journal Lancet, which showed that l'ocrelizumab is able to significantly slow down the progression of disability i…
A major phase III international clinical trial, led by Queen Mary University in London, has shown that ocrelizumab can significantly slow the progression of disability in people with progressive primary multiple sclerosis (PMS), even in older patients with advanced forms of disease who already need wheelchairs. The results of the study, called ORATORIO-HAND and published in The Lancet magazine, are based on more than 1,000 patients in 22 countri…
Ocrelizumab slows disability progression in advanced progressive multiple sclerosis
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.
Ocrelizumab cuts disability progression in primary progressive MS trial
A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.
Antibody Drug Slows Disability Progression in Advanced Multiple Sclerosis
Results from the Phase III ORATORIO-HAND study show that ocrelizumab, an antibody drug already prescribed to some patients with multiple sclerosis (MS), could benefit a much larger patient population, including those who are older or at more advanced stages of the disease. Published today in The Lancet, these findings could change the way clinicians understand and manage MS. “Our study suggests we should think differently about what successful …
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
